Immunovant Inc (IMVT)

Dec 27, 2024, 10:50 AM EST - 21 days ago

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 11, 2024, 6:25 AM EST - 5 weeks ago

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Nov 7, 2024, 6:30 AM EST - 2 months ago

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Oct 29, 2024, 6:30 AM EDT - 2 months ago

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Sep 9, 2024, 9:12 AM EDT - 4 months ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN

Sep 9, 2024, 3:55 AM EDT - 4 months ago

Immunovant Provides Update on Graves' Disease Development Program

Sep 5, 2024, 6:30 AM EDT - 4 months ago

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Aug 6, 2024, 8:25 AM EDT - 5 months ago

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

FIP FTAI OABI PRPL REAL RICK

May 29, 2024, 4:01 PM EDT - 8 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Apr 4, 2024, 2:12 AM EDT - 10 months ago

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Mar 12, 2024, 7:30 AM EDT - 11 months ago

Immunovant Awarded U.S. Patent for IMVT-1402

Feb 12, 2024, 7:00 AM EST - 1 year ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Jan 9, 2024, 9:00 AM EST - 1 year ago

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

BUR LQDA

Jan 3, 2024, 8:00 AM EST - 1 year ago

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 4:30 PM EST - 1 year ago

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 14, 2023, 1:24 PM EST - 1 year ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT

Nov 28, 2023, 7:00 AM EST - 1 year ago

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Nov 14, 2023, 3:48 AM EST - 1 year ago

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

Nov 13, 2023, 8:00 AM EST - 1 year ago

Immunovant to Present at Upcoming Investor Conferences

Nov 9, 2023, 7:00 AM EST - 1 year ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Oct 2, 2023, 4:52 PM EDT - 1 year ago

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 27, 2023, 11:41 PM EDT - 1 year ago

Immunovant Announces Pricing of $450 Million Common Stock Financing

Sep 27, 2023, 5:30 AM EDT - 1 year ago

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

Sep 26, 2023, 5:00 PM EDT - 1 year ago

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Sep 26, 2023, 4:20 PM EDT - 1 year ago

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Sep 26, 2023, 11:10 AM EDT - 1 year ago

Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)

Sep 26, 2023, 7:57 AM EDT - 1 year ago

Immunovant shares surge after antibody treatment succeeds in early-stage study

Sep 26, 2023, 6:00 AM EDT - 1 year ago

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Sep 25, 2023, 11:01 PM EDT - 1 year ago

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Jul 19, 2023, 5:50 PM EDT - 1 year ago

Immunovant Stock: With Anti-FcRn Validation Continuing, This Is A Must-Watch

May 24, 2023, 1:14 PM EDT - 1 year ago

Immunovant Could Be Poised For A Breakout In H2 2023

May 22, 2023, 7:00 AM EDT - 1 year ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Feb 3, 2023, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

Jan 8, 2023, 8:47 AM EST - 2 years ago

Immunovant: argenx At A 10% Valuation, Initiating With A Buy Rating

Nov 7, 2022, 8:00 AM EST - 2 years ago

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Nov 4, 2022, 7:00 AM EDT - 2 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

Oct 17, 2022, 3:10 PM EDT - 2 years ago

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 4, 2022, 8:45 AM EDT - 2 years ago

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Sep 28, 2022, 10:45 AM EDT - 2 years ago

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Sep 21, 2022, 8:00 AM EDT - 2 years ago

Immunovant to Present at Roivant Investor Day on September 28th

Sep 9, 2022, 8:00 AM EDT - 2 years ago

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Sep 7, 2022, 7:11 AM EDT - 2 years ago

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

Sep 7, 2022, 6:30 AM EDT - 2 years ago

Immunovant Announces Two New Development Programs for Batoclimab

Aug 24, 2022, 8:00 AM EDT - 2 years ago

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

Aug 5, 2022, 7:00 AM EDT - 2 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

Jun 9, 2022, 11:58 AM EDT - 2 years ago

Immunovant, Inc. (IMVT) CEO Pete Salzmann on Q4 2022 Results - Earnings Call Transcript

Jun 8, 2022, 9:31 AM EDT - 2 years ago

Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year

Jun 8, 2022, 7:00 AM EDT - 2 years ago

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022